Clinical Trials on Familial Alzheimer Disease in Japan

Total 6962 results

Kyoto University
Osaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaborators

Completed

Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease (REBRAnD)

Familial Alzheimer Disease (FAD) | PSEN1 Mutation

Japan
Washington University School of Medicine
National Institute on Aging (NIA); Alzheimer's Association; Eisai Inc.; Accelerating...

Recruiting

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, Argentina, Australia, Colombia, Netherlands, Puerto Rico, Spain, United Kingdom, France, Ireland, Mexico, Brazil, Japan, Germany
Washington University School of Medicine
Eli Lilly and Company; Hoffmann-La Roche; Avid Radiopharmaceuticals; National Institute... and other collaborators

Recruiting

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, Argentina, Australia, Colombia, France, Ireland, Mexico, Netherlands, Puerto Rico, Spain, United Kingdom, Brazil, Japan, Germany
Eisai Co., Ltd.

Completed

Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease

Alzheimer's Desease

Japan
Translational Research Center for Medical Innovation...
Daiichi Sankyo Co., Ltd.

Completed

Exploratory Study for the Validity of QuQu Scale (QuQu)

Alzheimer Dementia

Japan
Janssen Pharmaceutical K.K.

Completed

Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia

Alzheimer's Disease

Japan
Translational Research Center for Medical Innovation...
Daiichi Sankyo Co., Ltd.

Completed

Verification Study and Reactivity Study for the Validity of QuQu Scale (QuQu)

Alzheimer's Disease Dementia | Cognitive Concern Without Dementia

Japan
Osaka City University

Unknown

Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease

Alzheimer's Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease

Alzheimer Disease

Japan
Avid Radiopharmaceuticals

Withdrawn

Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians

Alzheimer's Disease

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease

Alzheimer's Disease

Japan
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Study of Florbetapir (18F) in Japanese Healthy Volunteers

Alzheimer's Disease

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531

Alzheimer Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Safety and Efficacy of MT-4666

Alzheimer's Disease

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males

Healthy | Alzheimer Disease

Japan
Eisai Co., Ltd.

Completed

Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice

Alzheimer's Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Terminated

Safety Study of MT-4666 in Subjects With Alzheimer's Disease

Alzheimer's Disease

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males

Alzheimer Disease

Japan
Hoffmann-La Roche

Recruiting

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

Alzheimers Disease

Korea, Republic of, United States, Canada, Poland, Spain, Australia, Japan, Chile, United Kingdom
Kyowa Kirin Co., Ltd.

Completed

A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.

Alzheimer's Disease

Japan
Novartis Pharmaceuticals
Ono Pharmaceutical Co. Ltd

Completed

Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Mirai Iryo Research Center, Inc.

Completed

Intensive Instruction on the Use of Aricept

Alzheimer's Type Dementia

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease

Alzheimer Disease

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects

Healthy | Alzheimer Disease

Japan
Chugai Pharmaceutical

Completed

A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients

Alzheimer's Disease

Japan
Janssen Pharmaceutical K.K.

Completed

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Alzheimer's Disease

Japan
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
National Center of Neurology and Psychiatry, Japan

Terminated

Transcranial Direct Current Stimulation for Depression in Alzheimer's Disease Patient - Preliminary Research (ADAPT)

Depression | Alzheimer Disease

Japan
Eli Lilly and Company

Completed

Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease

Alzheimer's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Agitation Associated With Dementia of the Alzheimer's Type

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Agitation Associated With Dementia of the Alzheimer's Type

Japan
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Terminated

Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Agitation Associated With Dementia of the Alzheimer's Type

Japan
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

Japan
Osaka University
Kowa Company, Ltd.

Terminated

The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease (PIT-ROAD)

Alzheimer Disease | Hypercholesterolemia

Japan
Eisai Co., Ltd.

Recruiting

A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab

Alzheimer's Disease

Japan
Pfizer

Completed

The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin

Transthyretin Familial Amyloid Polyneuropathy

Japan
Sound Wave Innovation CO., LTD.

Recruiting

A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease

Alzheimer Disease, Early Onset

Japan
Biogen

Completed

Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease (PROPEL)

Alzheimer's Disease

Japan
Novartis Pharmaceuticals
Amgen; Banner Alzheimer's Institute

Terminated

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS2)

Alzheimers Disease

Spain, United States, Belgium, Italy, Germany, Australia, Israel, Taiwan, Japan, Canada, Korea, Republic of, United Kingdom, France, China, Argentina, Finland, Singapore, Portugal, Chile, Mexico, Switzerland, Netherlands, Iceland, Puerto... and more
Pfizer

Completed

Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Eisai Co., Ltd.

Completed

A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Alzheimer's Disease

Japan
Eli Lilly and Company

Completed

A Study of LY3002813 in Participants With Alzheimer's Disease

Alzheimer Disease

United States, Japan
Pfizer

Completed

A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Eli Lilly and Company

Completed

A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

Alzheimer Disease

United States, Japan
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Terminated

Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Novartis Pharmaceuticals

Completed

NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients. (ENA1stepswitch)

Mild to Moderate Alzheimer's Disease

Japan
Novartis Pharmaceuticals
Ono Pharmaceutical Co. Ltd

Completed

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Alzheimer's Disease

Japan
Eli Lilly and Company

Terminated

A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

Healthy | Mild Cognitive Impairment | Alzheimer's Disease

United States, Japan
Eisai Inc.

Completed

A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia

Alzheimer's Type Dementia

Japan

3

Subscribe